Sat September 14, 2013
Biotech Investing: Catching the Next Wave
SEE EVENT DETAILS
at San Jose Airport Garden Hotel
(see times)
Biotech is once again the best performing sector in the Stock Market and the Medical Technology Stock has produced outstanding returns for its subscribers. Through 7/25: Model Portfolio +56.4%,
Trader's Portfolio +104.1%. This presentation will show individual investors how they may profit
from Biotech stocks or ETFs and also manage risk.
Over the last year, we have sharpened our focus and teamed up with Jay Silverman, a first class Wall Street biotech analyst. We have also re-launched our website, https://www.bioinvest.com, a one-stop-shop for all of your biotech investing needs. Our recent series of "White Papers" provides a deep and thorough understanding of our investment philosophy in biotech. Jay and I have over 50 years of combined biotech investment experience allowing us to provide world class biotech investment advice.
Take a peek at our website, https://www.bioinvest.com, where we have many features available to sample for free. Lastly, we want to invite you to hear us present at the Silicon Valley AAII for our most up-to-date recommendations in the exciting field of biotech investing.
Discussed By: John McCamant
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.
His expertise in biotechnology investments is a subject of media investment. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.
show less
Trader's Portfolio +104.1%. This presentation will show individual investors how they may profit
from Biotech stocks or ETFs and also manage risk.
Over the last year, we have sharpened our focus and teamed up with Jay Silverman, a first class Wall Street biotech analyst. We have also re-launched our website, https://www.bioinvest.com, a one-stop-shop for all of your biotech investing needs. Our recent series of "White Papers" provides a deep and thorough understanding of our investment philosophy in biotech. Jay and I have over 50 years of combined biotech investment experience allowing us to provide world class biotech investment advice.
Take a peek at our website, https://www.bioinvest.com, where we have many features available to sample for free. Lastly, we want to invite you to hear us present at the Silicon Valley AAII for our most up-to-date recommendations in the exciting field of biotech investing.
Discussed By: John McCamant
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.
His expertise in biotechnology investments is a subject of media investment. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.
Biotech is once again the best performing sector in the Stock Market and the Medical Technology Stock has produced outstanding returns for its subscribers. Through 7/25: Model Portfolio +56.4%,
Trader's Portfolio +104.1%. This presentation will show individual investors how they may profit
from Biotech stocks or ETFs and also manage risk.
Over the last year, we have sharpened our focus and teamed up with Jay Silverman, a first class Wall Street biotech analyst. We have also re-launched our website, https://www.bioinvest.com, a one-stop-shop for all of your biotech investing needs. Our recent series of "White Papers" provides a deep and thorough understanding of our investment philosophy in biotech. Jay and I have over 50 years of combined biotech investment experience allowing us to provide world class biotech investment advice.
Take a peek at our website, https://www.bioinvest.com, where we have many features available to sample for free. Lastly, we want to invite you to hear us present at the Silicon Valley AAII for our most up-to-date recommendations in the exciting field of biotech investing.
Discussed By: John McCamant
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.
His expertise in biotechnology investments is a subject of media investment. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.
read more
Trader's Portfolio +104.1%. This presentation will show individual investors how they may profit
from Biotech stocks or ETFs and also manage risk.
Over the last year, we have sharpened our focus and teamed up with Jay Silverman, a first class Wall Street biotech analyst. We have also re-launched our website, https://www.bioinvest.com, a one-stop-shop for all of your biotech investing needs. Our recent series of "White Papers" provides a deep and thorough understanding of our investment philosophy in biotech. Jay and I have over 50 years of combined biotech investment experience allowing us to provide world class biotech investment advice.
Take a peek at our website, https://www.bioinvest.com, where we have many features available to sample for free. Lastly, we want to invite you to hear us present at the Silicon Valley AAII for our most up-to-date recommendations in the exciting field of biotech investing.
Discussed By: John McCamant
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.
His expertise in biotechnology investments is a subject of media investment. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.
show less
Category:
Date/Times:
San Jose Airport Garden Hotel
1740 N. 1st Street, San Jose, CA 95112
The Best Events
Every Week in Your Inbox
From Our Sponsors
UPCOMING EVENTS
Great suggestion! We'll be in touch.
Event reviewed successfully.